VolitionRx (NYSE:VNRX) N.V. is a multi-national epigenetics company dedicated to developing simple, blood-based diagnostic tests for the early detection and management of cancer and other major diseases. Founded in 2008 as a spin-out from the Vrije Universiteit Brussel, the company has pioneered a novel platform that leverages the biochemical signatures of circulating nucleosomes—structures that package DNA—to identify disease-specific patterns. By focusing on robust, cost-effective assays, VolitionRx aims to transform disease screening and monitoring through minimally invasive procedures.
The company’s core offering, branded as the Nu.Q™ test series, consists of immunoassays designed to quantify and characterize circulating nucleosomes in patient blood samples. These assays are applicable to a broad range of indications, with ongoing research and development efforts targeting colorectal, lung, pancreatic, liver and other cancers. VolitionRx’s technology platform combines proprietary antibodies with standard laboratory workflows, enabling seamless integration into existing pathology and clinical laboratory environments.
Headquartered in Belgium, VolitionRx has established operating subsidiaries and research facilities in the United States, United Kingdom and Singapore, allowing it to engage with global clinical partners and regulatory bodies. Over the years, the company has entered collaborative agreements with leading academic institutions, contract research organizations and healthcare providers to advance clinical validation studies. These partnerships underpin VolitionRx’s strategic goal of securing regulatory approvals and expanding its commercial footprint across Europe, North America and Asia-Pacific.
VolitionRx is guided by a seasoned leadership team and board of directors with deep expertise in diagnostics, biotechnology, regulatory affairs and commercial development. The management group combines industry veterans in medical devices and life sciences with scientific founders who hold advanced degrees in molecular biology and oncology research. Together, they oversee the company’s ongoing efforts to refine its diagnostic platforms, pursue regulatory milestones and bring innovative screening solutions to clinicians and patients worldwide.
